Podcasts about dostarlimab

Program notes:0:47 Gun injuries and deer hunting season1:47 Other associated injuries2:47 Coincidence of hunting?3:48 Restrict hunting guns to that use4:10 Can we avoid surgery in some with cancer?5:10 Dostarlimab treatment6:10 Can help avoid surgery in few who have this mutation7:10 Look at specific pathways7:30 Lung cancer treatment8:32 71% responded9:12 Impact of Pepfar funding freeze10:12 Looked at waiver scenarios11:12 Decreased deaths and infection12:13 Takes time to resume13:06 End

Welcome back to today's Friday Review where I'll be breaking down the best of the week!     I'll be sharing specifics on these topics:     Weekly Podcast Recap Coros Pace 3 vs. Apple Watch (product review) Dostarlimab and Endometrial & Colorectal Cancer (research)   For all the details tune in to today's Cabral Concept 3290 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3290 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

In this episode, Alexa Basilio, PharmD, BCOP and Jessica Davis, PharmD, BCOP, CPP discuss immune-related adverse events and toxicities among patients using immune checkpoint inhibitors. This overview will include discussion about: How and when to monitor and treat mild vs severe immune-related toxicitiesThe art of balancing and tapering low-dose and high-dose corticosteroidsDifferentiating between immune-related and chemotherapy- or targeted therapy–associated adverse events for optimal management approachesInvolvement of multidisciplinary teams early during treatment to prevent immune-related adverse eventsImportance of educating patients, caregivers, and providers on immune-related toxicitiesPresenters: Alexa Basilio, PharmD, BCOPUniversity of Florida College of Pharmacy Oncology Pharmacy Specialist McKesson, The US Oncology NetworkTampa, Florida Jessica Davis, PharmD, BCOP, CPP Levine Cancer InstituteClinical Pharmacist Coordinator, Adult Hematology/OncologyAtrium Health Levine CenterCharlotte, North Carolina Link to full program: https://bit.ly/3We4HJy

Dr. Shannon Westin and her guest, Dr. Brian  Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors” recently published in the JCO and presented at the 2024 International Gynecologic Cancer Society. TRANSCRIPT The guest's disclosures can be found in the transcript.  Dr. Shannon Westin: Hello, and welcome to another episode of JCO After Hours, the podcast where we get in depth on manuscripts and literature published in the Journal of Clinical Oncology. I'm your host, Shannon Westin, gynecologic oncologist and JCO Social Media Editor by trade. I am thrilled because we are going to be talking about gynecologic cancer today. So, this is my jam. And specifically, we're going to be talking about a manuscript that's a simultaneous publication in the Journal of Clinical Oncology and presented at the Annual Meeting of the International Gynecologic Cancer Society on October 16, 2024. And this is “Pembrolizumab or Placebo, Plus Adjuvant Chemotherapy, With or Without Radiotherapy for Newly Diagnosed High Risk Endometrial Cancer: Results in Mismatch Repair Deficient Tumors.” This is affectionately the KEYNOTE-B21 trial, also known as the GOG-3053 trial and the ENGOT-en11 trial. And we are joined today by the primary author in this manuscript, Dr. Brian Slomovitz, who is the Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, and the clinical trial advisor in uterine cancer for the Gynecologic Oncology Group foundation. Welcome, Brian. Dr. Brian Slomovitz: Hey, thanks, Shannon, so much. It's a pleasure to be here. And thanks for giving us the opportunity to discuss this trial. Dr. Shannon Westin: Yes, it's a great trial and I'm so excited to talk about it. And I think we'll start just because this is a broad group that listens to this podcast, they're not all GYN oncologists, experts like yourself, so can you just level set a little bit and speak a bit about the incidence and mortality of endometrial cancer overall and the recent trends in this disease? Dr. Brian Slomovitz: Yeah, sure. So, and it is nice to speak about gynecologic cancers, as we know, endometrial cancer was and still is the most common of all gynecologic cancers. The numbers are going up. Right now, there's about 65,000 to 70,000 cases each year in the US diagnosed with endometrial cancer. The numbers are going up. A lot of its obesity related, some other factors, but as the population gets less healthy, those are some of the risk factors for the disease. The thing that, however, is quite surprising is that we're seeing the deaths due to endometrial cancer going up as well, while for other diseases, we're making slow, steady steps to try to decrease the mortality we're actually seeing an increase in mortality. And the most discouraging point, Shannon, as you know is the number of deaths from endometrial cancer is going to outnumber the number of deaths from ovarian cancer if it hasn't done it already. I mean, now's the time. So, we really need to come up with better treatment strategies to everything to decrease the incidence of disease, to help with prevention, but for those poor women who are diagnosed, to come up with better treatment options so we don't have to keep this increasing trend in mortality. Dr. Shannon Westin: Absolutely. And I think some of that is related and we don't need to get on a soapbox here, but the amount of funding that goes towards research in endometrial cancer, and of course you, you have been leading the way and really trying to get a ton of trials in this space and getting our industry partners and our government partners to really support this. So really just commending you on how much you've worked on, on this area. And to that end, we've had a huge renaissance with immunotherapy and endometrial cancer, a lot of really big trials. Why don't you give the audience a rundown of where, so far, this seems to be best utilized for people with endometrial cancer? Dr. Brian Slomovitz: Thanks for that. And as you sort of alluded to, it's been a revolution, really, with immunotherapy. We started off at immunotherapy looking at microsatellite instability or the dMMR patients. What we found is similar to other disease sites in the second and third line setting that we saw good activity with the single agent checkpoints, pembrolizumab dostarlimab, that's based on the earlier KEYNOTE data and the GARNET trial. Really, a landmark study in the second line was Vicki Makker and her colleagues put pembrolizumab and lenvatinib combination for those patients with the cold tumors. Not the dMMRs or MSI Highs, but the proficient mismatch repair. And that study in a second line setting found that it was better than chemotherapy for an overall survival advantage. So right there, we know that it works in the second line setting in the dMMR population, and we got an indication in the PMR population saying that immunotherapy works in all women with endometrial cancer at some point, then we really had the groundbreaking trials. And Shannon, thank you. You are the leader on one of the four trials that happened, to DUO-E, AtTEnd, GY018 and RUBY trial, all very similar studies showing that the combination of immunotherapy with chemotherapy in the first line, metastatic or recurrent setting had a better outcome for patients than if given chemotherapy alone. That actually led to amazing things. We had three of those drugs have FDA approvals, pembrolizumab for all comers, dMMR and PMMR in the first line metastatic setting with chemotherapy; Dostarlimab, PMR, dMMR in the first line or metastatic with chemotherapy. And Shannon, in your study, I think we still have to learn a lot from your study. DUO-E, chemotherapy plus minus dostarlimab. And you also added a PARP inhib, and those patients with a PARP did better. So I'm really looking forward to your data, to the subgroup analysis to figure out which of those patients, depending on the biomarker, do better with PARP therapy. And right now, you have a dMMR FDA indication. But who knows? The future is really exciting to see- to be splitters, not lumpers. And I really want to see how that data pans out. And so that's how it came into the first and second line setting and that led us really to come up with the idea for this trial to put it into the adjuvant setting. Dr. Shannon Westin: Right. And so, I think this would be really important because we're so ingrained in this. We see this on the day to day. Can you kind of tease out a little bit what's different about those patients that would be treated in that advanced recurrent setting versus the patients that would be potentially treated in this B21 study? Dr. Brian Slomovitz: Yeah, so the first step, we demonstrated the efficacy in patients that really the treatment options were an unmet need. In the second line setting, we didn't have good treatment options. Those are the patients with measurable disease, with symptomatic disease giving immunotherapy. And not only did we see the efficacy, which was better, but we also were able to give it with limiting the side effects as seen with chemotherapy, which is nice. And then we know that the first line therapy, traditionally for endometrial cancer with carboplatin paclitaxel, response rates about 50%, progression free survival about a year, really something that we needed to improve upon. So, adding immunotherapy to the platinum backbone therapy really demonstrated an advantage. But now what we want to do is we want to see if we could prevent, in the high-risk patients, those without disease, what can we do to help prevent the disease from recurring and help patients live longer without really the need for really lifesaving types of treatments? We want to prevent it from recurring. Dr. Shannon Westin: Yeah, I think that's essential. We know that if we can sit on that prevention side and kind of invest all the time and effort that we need to upfront, that really does yield the longer survival. So why don't you just walk through the overall design of this trial, please? Dr. Brian Slomovitz: Yeah. So, this was an all-comers trial, meaning in individuals that had high risk endometrial cancer, high risk for recurrence, that included, in endometrial cancer, we have aggressive histologic subtypes, serous histologies, clear cell histologies, any stage, as long as there was some myometrial invasion. We also, for the first time, included patients looking at the molecular subclassifications. So, if there was a P53 mutation and they were stage 1 with myometrial invasion, they were included. And then in all comers, any patients with stage 3 or up to 4a disease, as long as the surgery was for a curative intent, and they had no residual disease after surgery, then they were allowed to enroll into this trial. One of the things is that this is the first time we've done an adjuvant trial this large. I think one of the reasons that helped us succeed in doing a trial like this is that we left radiation as investigator's choice, because a lot of times going into a trial like this, people feel strongly, we know our radiation oncology colleagues, rightfully so, feel that radiation could help prevent disease from coming back. And we also have the camp that says they don't need radiation. We took that question out of this study. We let investigators decide whether or not they're going to get radiation. It was for patients to get chemotherapy, who are going to normally get chemotherapy for their high-risk disease and randomize them to chemotherapy plus placebo or chemotherapy plus pembrolizumab, a PD-1 inhibitor, in order to see if we could prevent the disease from coming back. Dr. Shannon Westin: And the primary results of this study were just presented at ESMO and published in the Annals of Oncology. Can you give us just a quick overview of what that was, what they found? Dr. Brian Slomovitz: Yep. So, we enrolled 1100 patients. The primary objective of the study was to look at the ITT population, progression free survival and overall survival. And the overall study was negative. Okay, so the hazard ratio in the ITT population was 1.02, not demonstrating a benefit of adding pembrolizumab in this population. I would say disappointing, but at the same point, something that we could really learn a lot from and somewhere that we know that in the whole population, we need to come up with better strategies to help prevent recurrence of disease, better adjuvant treatment strategies. But there's also information that we learned from this trial and that we're reporting on that we're actually super excited about and we feel may be game changing. Dr. Shannon Westin: Yeah. So, let's go to that. This is the good news. Your manuscript in the JCO, thank goodness you published it here, was focused on that subset of mismatch repair deficient. So, tell us what you found. Dr. Brian Slomovitz: So, in this study, we found that the first stratification factor was dMMR versus pMMR. Now, in the pMMR group, those patients had further stratification factors, but dMMR by itself was a stratification factor. Amongst those patients that had dMMR tumors, we found the hazard ratio to be 0.31 benefiting those patients who received pembrolizumab in the adjuvant setting. Really something that when we look at the treatment studies, the GY018s, the RUBYs, the atTEnds, the DUO-Es, in a dMMR setting, we see a similar hazard ratio of 0.3, 0.4. But to get that hazard ratio, which was statistically significant, obviously, is something that we were quite pleased with and something that we felt was worthy of reporting further. I will say it was a pre-specified endpoint. We didn't allocate alpha to it. So, at the beginning, it was a pre-specified endpoint, but at the same time even though we didn't specify alpha towards that outcome, it still, we feel is clinically meaningful and can definitely add to affect the standard of care and the management of these patients. Dr. Shannon Westin: Yeah. I'm very intrigued to see what kind of people do with this. It makes sense, mechanistically, it makes sense if there was a population that was going to benefit, if not everybody does, this is the group that will. I mean, do you feel like there's enough data? What are you going to do? FDA approval aside, obviously, those kinds of things. But how do you feel about this? Is this something you're going to offer to your patients? Dr. Brian Slomovitz: The first answer is yes. I think it's something that I would like to offer my patients. As you know, we need one of two things: we either need an FDA approval or for a lot of our payers required to be in the NCCN listings. I don't serve on the committee. I have no influence on NCCN. I'm excited to see how they'll respond to not only the Annals article, but obviously in today's release of the JCO article, I hope that they'll look upon it favorably. It's a drug that we're used to giving. Pembrolizumab, we have a lot of experience with it. It's interesting. We didn't see any new safety signals, Shannon. Dr. Shannon Westin: Yeah, I was going to ask - that's great. Dr. Brian Slomovitz: There was nothing, nothing additional that we found in this trial. So, I feel that it can definitely improve the outcome of those patients, in my view, with high risk for recurrence, treating pembrolizumab in this setting. Dr. Shannon Westin: Yeah, I think it's important, of course, to look at the safety. What about quality of life? Any new findings there? Dr. Brian Slomovitz: Yeah, we did that quality of life as part of the phase 3 trial. No difference between the two arms. No difference between the two arms. When we looked at a couple of the other analyses, we found that the benefit is the same on stage 3, 4 tumors. We saw that the benefit was there as well. So, there were less patients in the stage 1, 2 group. But I think really, for all comers, for the patient population, I would definitely consider giving pembrolizumab, again, for those patients with a deficient mismatch repair. Dr. Shannon Westin: It's really exciting, and I think you mentioned some of the statistical limitations. Anything else that gives you pause about the study or things you wish you did better? I know we always like to armchair quarterback ourselves after we do these kinds of studies. Dr. Brian Slomovitz: Yeah, it's interesting. When we designed the study years ago, we used the best information we had at that time to come up with the study design, and we're happy with it, and we really don't think that we could have done it much better. I should say, this was a great partnership that we had here between the GOG, ENGOT and with sponsor Merck, Toon Van Gorp was the lead PI of the global trial. When he gave me the good opportunity to present it at the IGCS and to be the lead author on this, it was really a great partnership. And when we came up with a trial years ago, it was the best trial that we thought at that time. And based on the information now, I think it's really something that we're excited about these results, even though the overall trial was negative. Dr. Shannon Westin: Yeah, I agree with you. I think it's interesting, it's informative to think about, “Well, what would we do now or then if we knew what we knew now?” But still, you design the trial the best way you can. I think the results are super intriguing. I'm hopeful at the way they'll be reviewed. I agree I don't have any inside information about the NCCN committee, but I do hope that they'll consider the overarching data to support immunotherapy and mismatch repair deficiency and the findings of this study. And then I guess the last question I would just ask, as you're an expert here, what are you looking forward to seeing coming next in this space? What's the stuff you're intrigued about in endometrial cancer? Dr. Brian Slomovitz: I think, Shannon, you and I have talked about this for a while. I think we're getting really close to eliminating chemotherapy for some of the patients who suffer from this disease. So, I'm not sure if we'll do a follow up to this trial, but I think a logical type of follow up would be to see: what if we just took away chemotherapy altogether and we did pembro in the adjuvant setting, pembrolizumab versus chemotherapy? We don't have that trial in the adjuvant setting, but actually, we completed accrual of that trial in the recurrent setting and we're anxiously awaiting those results. That's KEYNOTE-C93, where in the dMMR population we studied pembrolizumab versus carboplatin paclitaxel. How those results may translate into this setting, I'm not sure. Right now, it's exciting what we have, but yeah. And I think future is bright for this. Just to highlight, in the two arms, there's 140 patients approximately in each arm; there were 25 recurrences in those patients who received placebo. Only eight recurrences in those that received pembrolizumab. Really, when we talk about numbers, it's really remarkable and it shows you the benefit it really had on the patients. Dr. Shannon Westin: Well, this was great. It flew by, as it always does when I'm having conversations with you. I just really want to thank you again for taking the time to share your knowledge with our listeners. Dr. Brian Slomovitz: Thanks, Shannon. Dr. Shannon Westin: And listeners. Thank you all for taking the time to hear about endometrial cancer. Again, this was “Pembrolizumab or Placebo, Plus Adjuvant Chemotherapy, With or Without Radiotherapy for Newly Diagnosed High Risk Endometrial Cancer Results in Mismatch Repair Deficient Tumors.” And this was the JCO After Hours. If you loved what you heard, please check out wherever you get your podcast to see what else we have to offer. Have an awesome day.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.        

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian CancerATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian CancerPhase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα ExpressionPhase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual DiseasePhase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer Program faculty:Ana Oaknin, MD, PhDHead of Gynaecologic Cancer ProgrammeDepartment of Medical OncologyVall d' Hebron University HospitalVall d'Hebron Institute of Oncology Barcelona, SpainAlexandra Leary, MD, PhDCo-Director, Department of Medical OncologyMedical Oncologist, GynecologyTeam Leader, Gynecologic Translational Research Lab, Institut Gustave RoussyParis, FranceResources:To download the slides associated with this podcast discussion, please visit the program page.

Dr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

CancerNetwork® spoke with Ritu Salani, MD, about the expanded FDA approval of dostarlimab-gxly (Jemperli) in combination with carboplatin/paclitaxel for patients with primary advanced or recurrent endometrial cancer.1  Salani, a board-certified gynecologic oncologist and director of Gynecologic Oncology at the University of California, Los Angeles Health, discussed the clinical benefit the dostarlimab combination showed for patients with endometrial cancer, particularly those with mismatch repair-deficient (dMMR) tumors, in the phase 3 RUBY trial (NCT03981796). Data leading to the approval showed a statically significant progression-free survival (PFS) and overall survival (OS) benefit in patients with dMMR or microsatellite-instability high (MSI-H) endometrial cancer, as well as for those across the overall population. Noting the significant impact dostarlimab had on survival benefit without significant added toxicity, which investigators reported as early as March 2023, Salani said it was “wonderful” to have a relatively short turnaround time in making the combination therapy available for patients with primary advanced or recurrent endometrial cancer. Beyond the particular benefit among patients with dMMR tumors, she expressed the need to improve outcomes for patients with mismatch repair-proficient (pMMR) or microsatellite stable (MSS) tumors, who did not experience as much of a pronounced benefit from treatment with dostarlimab. Salani also addressed the role of immunotherapy in subsequent lines of treatment following frontline therapy. Being thoughtful about sequencing agents in this setting may be an optimal strategy to give patients the greatest survivability and quality of life. She also considered alternative treatment strategies for certain patients, such as those with pMMR tumors.  “The thing that is interesting is the study highlighted patients who had residual disease or measurable disease present when they were getting this therapy, and that seems to be where the most significant impact [is],” Salani said. “Seeing more data on the right selection of patients will be really important. There are other avenues of treatment for these patient populations, particularly the pMMR population, where you might see some other therapies that may have an equally profound impact as immunotherapy. Maybe that will lend itself to leading immunotherapy for second-line treatment, if needed.” Reference FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy. News release. FDA. August 1, 2024. Accessed August 15, 2024. https://tinyurl.com/mtr6tpyp

Send us a Text Message.Curious about the latest breakthroughs in oncology treatment? Prepare to have your perspective shifted and hopefully a few laughs too, as we dissect the most compelling research and clinical insights with our expert hosts, Professor Craig Underhill, Dr. Kate Clarke, and Professor Christopher Jackson. Today's episode covers an eclectic mix of papers from many different specialities. Craig tackles ASCO non-small cell lung cancer recommendations, sarcomas in Brazil and cardiovascular risks in cancer patients.Kate dives into endometrial cancer, the HIMALAYA study and CAR-T.CJ looks at colon cancer, pancreatic cancer and pain management. And a shout-out to our Series 1 hosts Professor Eva Segelov and Professor Hans Prenen who both have papers in today's episode! For papers, bios and other links visit the Show Notes on our website.For the latest oncology news visit www.oncologynews.com.au.We invite healthcare professionals to join The Oncology Network for free - you'll also receive our free weekly publication The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancerRUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancerSurvival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancerDUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancerLong-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatinSubgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator's choice of chemotherapy in FR

Gynecologic oncology experts Dr. Matthew Powell from Washington University School of Medicine and Dr. Amanda Fader from Johns Hopkins Hospital discuss the increasing rates of endometrial cancer along with future directions of treatments and screenings. --- SYNPOSIS First, the physicians discuss trends in endometrial cancer rates and delve into the factors driving these trends, such as the obesity epidemic and aging population. They explore the differences between endometrioid and non-endometrioid cancers, along with the impact of racial and geographic disparities. The conversation also covers advances in diagnostics and treatments—including immunotherapy and targeted therapies—and the critical need for better awareness, screening practices, and research funding to combat this public health threat. --- TIMESTAMPS 00:00 - Introduction 03:11 - Types of Endometrial Cancer 04:44 - Rising Rates and Risk Factors 08:03 - Disparities in Endometrial Cancer Care 10:37 - Symptoms and Diagnosis 13:52 - Ultrasound vs. Biopsy 16:17 - Challenges in Biopsies 20:58 - Management/Treatment Approaches 23:03 - Geographic Disparities/Access to Care 26:07 - Vaginal Brachytherapy 32:11 - Innovations in Treatment and Research 40:34 - Future Directions: Endometrial Screening 43:54 - AI in Gynecologic Oncology --- RESOURCES Beavis, A. L., Blechter, B., Najjar, O., Fader, A. N., Katebi Kashi, P., & Rositch, A. F. (2023). Identifying women 45 years and younger at elevated risk for endometrial hyperplasia or cancer. Gynecologic Oncology, 174, 98–105. https://doi.org/10.1016/j.ygyno.2023.04.019 Mirza, M. R., Sharma, S., Roed, H., Landrum, L. M., Gilbert, L., Gold, M. A., Novák, Z., Edelson, M., Meirovitz, M., Diaz, J. P., Huygh, G., Buscema, J., Pothuri, B., Eshed, H. D., Coleman, R. L., Slomovitz, B. M., Kostadinov, R., Stevens, S., Ronzino, G., & Powell, M. A. (2024). Post hoc analysis of progression-free survival (PFS) and overall survival (OS) by mechanism of mismatch repair (MMR) protein loss in patients with endometrial cancer (EC) treated with Dostarlimab plus chemotherapy in the ruby trial. Journal of Clinical Oncology, 42(16_suppl), 5606–5606. https://doi.org/10.1200/jco.2024.42.16_suppl.5606 Society of Gynecologic Oncology (SGO): https://www.sgo.org/

The new drug Dostarlimab guides the body's immune system to recognise the cancer cells as harmful and kill them. Patients who followed the six months of treatment showed a complete clinical response with no evidence of tumours during follow-up exams.

Giving yourself grace to endure life's stresses and advocating for yourself when something feels “off” with your body can lead to your personal growth, self awareness – and in some cases – your own survival. When healthcare limitations and red tape become obstacles to seeking the healthcare answers you need, do not give up. Listen as Risky Benefits Podcast guest, Kelli Spills, shares her very personal cancer journey to help others gain perspective on the realities surrounding cancer symptoms, self advocacy when healthcare challenges don't lead to efficient and proper diagnosis, and how developing a treatment plan, or researching alternative treatment trials can promote mindful change and positive outcomes.If you also want to see Kelly's video that she speaks about, feel free to click & visit Stand Up To Cancer's YouTube page.MORE ABOUT OUR GUESTS:Kelly (Spill) Bonito3 Year Colorectal Cancer SurvivorFeatured on: Stand Up 2 Cancer, The Washington Post, NBC, Everyday Health, CBSKelly (Spill) Bonito is a 3 year colorectal cancer survivor due to immunotherapy. She started her journey with cancer when she was 28 years old. Her symptoms arose when she was 8 months pregnant with her son. She was brushed off from a handful of doctors telling her it was internal hemorrhoids. With persistence to self advocate, she finally found a provider who listened. Kelly's plan was to explore her options by visiting three cancer centers. She was looking to find her best fit by the feeling of comfort and best treatment option. Her first stop was Memorial Sloan Kettering and it ended up being her last stop. Her initial treatment plan was chemotherapy, oral chemotherapy/radiation, and surgery. This treatment option would lead her to never being able to carry another baby again, as well as, forever having a colostomy bag. This led her and her husband to freeze embryos prior to treatment in hopes to be able to bring another baby into this world. She arrived at her appointment to schedule her first day of chemotherapy and left that appointment with a new treatment plan. Kelly's tumor tested positive for a genetic mutation called MMrd, which allowed her to be a candidate for an immunotherapy now named Dostarlimab. Kelly made a brave decision being the fourth patient in the USA to undergo this treatment.Kelly is a wife,now a mother of two, runs her own health and wellness business, and is a patient advocate for Colorectal Cancer and clinical trials. She continues to advocate to bring hope and awareness for this cancer that is on the rise for individuals 50 and under. She used to be the quitest woman in the room, but now wants her voice heard on how important it is to self advocate. Kelly has been interviewed by CBS, NBC, and The Washington Post. She was featured on Stand Up 2 Cancer and currently writes a blog for To listen in and subscribe to more episodes, visit our website: fbmc.com/podcast.

Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.

In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICRCCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node dissection compared with simple hysterectomy and pelvic node dissection in low-risk, early-stage cervical cancer Final OS results from KEYNOTE-826: phase III study of CT with or without pembrolizumab as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancerDUO-O: a randomized, placebo-controlled phase III study of durvalumab plus carboplatin, paclitaxel, and bevacizumab and then maintenance bevacizumab, durvalumab, and olaparib in patients with newly diagnosed advanced ovarian cancer and no BRCA1/2 gene alteration MIRASOL: an initial report from a phase III study of mirvetuximab soravtansine vs investigator's choice of CT in platinum-resistant ovarian cancer with high expression of FRαPatient-reported outcomes from the phase III ENGOT-EN6/RUBY trial of dostarlimab plus standard-of-care CT in primary advanced or recurrent endometrial cancerPresenters:Kathleen Moore, MD, MSAssociate Director, Clinical ResearchDepartment of Gynecologic OncologyStephenson Cancer Center, University of OklahomaOklahoma City, OklahomaNicoletta Colombo, MD, PhDAssociate Professor of Obstetrics and GynecologyEuropean Institute of OncologyUniversity of Milan-BicoccaMilan, ItalyContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries: bit.ly/43Q5CBI

Dr Gilbert discusses the FDA approval of dostarlimab in patients with endometrial cancer, key efficacy data from the GARNET trial, and how this agent bolsters the endometrial cancer treatment paradigm.

Listen to a soundcast of the February 9, 2023, FDA approval of Jemperli (dostarlimab-gxly) for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen.

We were inspired by The Guardian's article about using sugar kelp to combat climate change so we are rerunning an episode of Boxerblu and Bram that teaches us about The Johnny Appleseed of Sugar Kelp!https://www.theguardian.com/environment/2023/mar/01/specieswatch-sugar-kelp-north-sea-carbon-climate-crisisThis episode covers: Elvis weddings being banned in Las Vegas by the company that owns Elvis's likeness; how parents in Killingly, Connecticut don't want mental health care in their schools; Shuvinai Ashoona's Arctic Art; an experimental rectal cancer drug that showed a 100% success rate; and the Johnny Appleseed of Sugar Kelp farming

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including:Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placeboPhase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced ovarian cancerPhase III ATHENA-MONO: outcomes by disease subgroups receiving rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancerPhase III ARIEL4: OS outcomes following treatment with rucaparib vs chemotherapy in patients with relapsed advanced ovarian cancer and a deleterious BRCA1/2 mutationPresenters:Domenica Lorusso, MD, PhDAssociate ProfessorGynecologic Oncology DepartmentClinical Research UnitFondazione Policlinico Gemelli IRCCSRome, ItalyAlexandra Leary, MD, PhDMedical Oncologist and Team LeaderGynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN

It's September 3rd, 2022. BoxerBlu and Bram are back. We learn that Bram will seek a behaviorist for a compulsion that he has and about the family's summer. Then we learn news for kids about Elvis's likeness being banned from Las Vegas chapels; mental health clinics being verboten in schools in Killingly, CT; an artist named Shuvinai Shoona who makes art in the Arctic Circle, a very successful rectal cancer trial of an experimental drug; and the Johnny Appleseed of sugar kelp farming  

It's September 3rd, 2022. BoxerBlu and Bram are back. We learn that Bram will seek a behaviorist for a compulsion that he has and about the family's summer. Then we learn news for kids about Elvis's likeness being banned from Las Vegas chapels; mental health clinics being verboten in schools in Killingly, CT; an artist named Shuvinai Shoona who makes art in the Arctic Circle, a very successful rectal cancer trial of an experimental drug; and the Johnny Appleseed of sugar kelp farming  

How to think about when and how to do RCTs? What are the limitations to observational studies? Smoking. Parachutes. Dostarlimab. Guarantee Time Bias. Confounding. Multiple Hypothesis testing and more

In this episode, Jubilee Brown, MD, and Elisabeth Diver, MD, provide expert insights on new data presented at ASCO 2022 for ovarian, endometrial, and cervical cancers regarding:Subgroup analyses from KEYNOTE-826 evaluating pembrolizumab in combination with chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancerPreliminary subgroup analyses from phase III ENGOT-EN5/GOG-3055 SIENDO trial of selinexor vs placebo maintenance in recurrent endometrial cancerUpdated analyses from phase I GARNET trial of dostarlimab in dMMR/MSI-H and pMMR/MSS advanced/recurrent endometrial cancer (cohorts A1 and A2)EndoBARR trial of atezolizumab, bevacizumab, and rucaparib in previously treated recurrent and progressive endometrial cancerPhase III ATHENA-MONO trial of first-line rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with advanced ovarian cancerPresenters:Jubilee Brown, MDProfessor and Division DirectorGynecologic OncologyLevine Cancer Institute, Atrium HealthCharlotte, North CarolinaElisabeth Diver, MDClinical Assistant ProfessorDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyStanford UniversityStanford Cancer InstituteStanford University Hospital and ClinicsStanford, CaliforniaContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/3ufB8Js

Pour écouter Comment j'ai bâti un empire:Apple Podcast:https://podcasts.apple.com/fr/podcast/mon-argent/id1569918922Spotify:https://open.spotify.com/show/6UduCKju82nA00KdBb08d9?si=KzkcGE8IRYOdR5m9hMbyZwDeezer:https://www.deezer.com/fr/show/2676812Google Podcast:https://www.google.com/podcasts?feed=aHR0cHM6Ly9yc3MuYWNhc3QuY29tL21vbi1hcmdlbnQ%3D------------------------------Certains patients, atteints d'un cancer rectal avancé, auraient été guéris par l'administration d'un médicament, le dostarlimab. Peut-on parler, en l'espèce, d'un remède miraculeux ?Un médicament stimulant le système immunitaire12 patients ont pris, toutes les 3 semaines et durant 6 mois, un médicament appelé dostarlimab. Ces personnes souffraient d'un cancer rectal localement avancé. Ils n'ont pas bénéficié, durant cette période, d'un autre traitement.Le dostarlimab, déjà utilisé pour traiter d'autres formes de cancer, fait partie de la catégorie des anticorps monoclonaux. Il agit en bloquant une protéine qui tend à réduire la réponse immunitaire.Ce type de médicament n'agit donc pas contre le cancer lui-même, mais met le système immunitaire en état de répondre à la menace qu'il représente.Des résultats très encourageantsEt le résultat est plus que concluant. Au point que certains médecins voient dans l'action de ce médicament une sorte de "première" dans le domaine des traitements anticancéreux.En effet, les 12 patients, c'est-à-dire la totalité de la cohorte suivie, sont entrés en rémission. Le cancer semble avoir disparu, les médecins ne percevant plus aucune trace des tumeurs, par toucher rectal ou d'autres examens.Aucun de ces patients n'a eu besoin d'une chimiothérapie ou d'une intervention chirurgicale, alors que les deux étaient prévus, au départ, pour accompagner ce traitement médicamenteux.Qui plus est, aucune des personnes concernée n'a constaté d'effets secondaires. Ils sont pourtant assez nombreux et parfois graves. En effet, une personne prenant du dostarlimab peut souffrir d'une inflammation respiratoire, d'une colite ou des manifestations de l'hyperthyroïdie.Ce traitement à base de dostarlimab semble donc très prometteur et représente un véritable espoir en terme de traitement anticancéreux.Toutefois, cet optimisme doit être tempérée par la petite taille de l'échantillon étudié. D'autres études seront donc nécessaires pour affiner les résultats obtenus. Par ailleurs, ce médicament se révèle moins efficace pout traiter d'autres formes de cancer.Le dostarlimab, délivré sur prescription médicale et supervisé par des médecins spécialistes, existe en France sous le nom de Jemperli. Il est utilisé dans le traitement de certains cancers et administré sous forme de perfusion. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Pour écouter Comment j'ai bâti un empire: Apple Podcast: https://podcasts.apple.com/fr/podcast/mon-argent/id1569918922 Spotify: https://open.spotify.com/show/6UduCKju82nA00KdBb08d9?si=KzkcGE8IRYOdR5m9hMbyZw Deezer: https://www.deezer.com/fr/show/2676812 Google Podcast: https://www.google.com/podcasts?feed=aHR0cHM6Ly9yc3MuYWNhc3QuY29tL21vbi1hcmdlbnQ%3D ------------------------------ Certains patients, atteints d'un cancer rectal avancé, auraient été guéris par l'administration d'un médicament, le dostarlimab. Peut-on parler, en l'espèce, d'un remède miraculeux ? Un médicament stimulant le système immunitaire 12 patients ont pris, toutes les 3 semaines et durant 6 mois, un médicament appelé dostarlimab. Ces personnes souffraient d'un cancer rectal localement avancé. Ils n'ont pas bénéficié, durant cette période, d'un autre traitement. Le dostarlimab, déjà utilisé pour traiter d'autres formes de cancer, fait partie de la catégorie des anticorps monoclonaux. Il agit en bloquant une protéine qui tend à réduire la réponse immunitaire. Ce type de médicament n'agit donc pas contre le cancer lui-même, mais met le système immunitaire en état de répondre à la menace qu'il représente. Des résultats très encourageants Et le résultat est plus que concluant. Au point que certains médecins voient dans l'action de ce médicament une sorte de "première" dans le domaine des traitements anticancéreux. En effet, les 12 patients, c'est-à-dire la totalité de la cohorte suivie, sont entrés en rémission. Le cancer semble avoir disparu, les médecins ne percevant plus aucune trace des tumeurs, par toucher rectal ou d'autres examens. Aucun de ces patients n'a eu besoin d'une chimiothérapie ou d'une intervention chirurgicale, alors que les deux étaient prévus, au départ, pour accompagner ce traitement médicamenteux. Qui plus est, aucune des personnes concernée n'a constaté d'effets secondaires. Ils sont pourtant assez nombreux et parfois graves. En effet, une personne prenant du dostarlimab peut souffrir d'une inflammation respiratoire, d'une colite ou des manifestations de l'hyperthyroïdie. Ce traitement à base de dostarlimab semble donc très prometteur et représente un véritable espoir en terme de traitement anticancéreux. Toutefois, cet optimisme doit être tempérée par la petite taille de l'échantillon étudié. D'autres études seront donc nécessaires pour affiner les résultats obtenus. Par ailleurs, ce médicament se révèle moins efficace pout traiter d'autres formes de cancer. Le dostarlimab, délivré sur prescription médicale et supervisé par des médecins spécialistes, existe en France sous le nom de Jemperli. Il est utilisé dans le traitement de certains cancers et administré sous forme de perfusion. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Stephen M. Ansell, MD, PhD, discusses efforts to identify new upfront treatment regimens to help extend OS in patients with relapsed or refractory classical Hodgkin lymphoma. :25 Lorenzo Cohen, PhD, shares his thought on the impact of acupuncture regimens on xerostomia and patients' quality of life. 5:26 Bradley J. Monk, MD, discusses the results of a study on the use of rucaparib monotherapy among women with advanced ovarian cancer 10:37 Christopher Manz, MD, MSHP, provides an overview of the results of the randomized PROStep trial, which assessed whether remote patient-reported symptoms and passive activity monitoring could improve patient-clinician communication about symptoms and functional status of patients with cancer. 18:09 Luke Maese, DO, discusses the results of the Children's Oncology Group AALL1931 study, its rationale, the potential implications of the findings and the questions that must be addressed in future research. 21:04     Read the full coverage here: https://www.healio.com/news/hematology-oncology/20220603/firstline-brentuximab-vedotin-regimen-extends-os-in-advanced-classical-hodgkin-lymphoma https://www.healio.com/news/hematology-oncology/20220609/acupuncture-benefits-patients-with-radiationinduced-xerostomia https://www.healio.com/news/hematology-oncology/20220606/rucaparib-shows-efficacy-as-firstline-maintenance-therapy-in-ovarian-cancer https://www.healio.com/news/hematology-oncology/20220610/more-work-to-do-in-oncology-to-collect-useful-data-about-symptoms-functional-status https://www.healio.com/news/hematology-oncology/20220611/intramuscular-recombinant-erwinia-asparaginase-active-safe-in-leukemia-lymphoma-subsets Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset Source: Cercek A, et al. Abstract LBA5. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Trastuzumab deruxtecan extends survival in HER2-low metastatic breast cancer Source: Modi S, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago. Disclosures: Ansell reports research funding to his institution from ADC Therapeutics; Affimed Therapeutics, AI Therapeutics, Bristol Myers Squibb, Regeneron, Seagen and Trillium Therapeutics, and honoraria from Research to Practice and WebMD. Cohen reports no relevant financial disclosures. Monk reports relationships with Clovis Oncology, Merck, Roche/Genentech and several other pharmaceutical companies. Manz reports no relevant financial disclosures. Maese reports consultant and speakers bureau roles with Jazz Pharmaceuticals.

When will a COVID-19 booster targeting Omicron be available? Find out this and more in today's PV Roundup podcast.

പ്രിയ സുഹൃത്തേ , ന്യൂയോർക്കിലെ പ്രശസ്തമായ Memorial Sloan Kettering Cancer Center (MSKCC ) അർബുദത്തിന് ഫലപ്രദമായ ഒരു മരുന്ന് വികസിപ്പിച്ചു എന്ന വാർത്ത ലോകത്തെ തെല്ലൊന്നുമല്ല ആശ്വസിപ്പിച്ചത് . MSKCC യിൽ അസ്സോസിയേറ്റ് പ്രൊഫസറായ മലയാളി ഡോക്ടർ വിജയ് ജോസഫ് പുതിയ കണ്ടെത്തലിൻ്റെ വിശദാംശങ്ങൾ പങ്കുവെയ്ക്കുന്നു ഈ പ്രത്യേക അഭിമുഖത്തിൽ . അദ്ദേഹം പ്രധാനമായും സംസാരിക്കുന്നത് ഇനിപ്പറയുന്ന വിഷയങ്ങളെക്കുറിച്ചാണ് . 1 . എന്താണ് Dostarlimab എന്ന പുതിയ മരുന്ന് മുന്നോട്ടുവെയ്ക്കുന്ന പ്രതിവിധി ? എത്രമാത്രം വിജയപ്രതീക്ഷ ഇതുനൽകുന്നു ? 2 . ഏതുതരം അർബുദങ്ങൾക്കാണ് പുതിയ മരുന്ന് ഫലപ്രദമാകാൻ ഇടയുള്ളത് ? 3 . എന്താണ് അർബുദചികിത്സാരംഗത്ത് Immunotherapy യിൽ നടക്കുന്ന പരീക്ഷണങ്ങൾ ? 4 . പുതിയ മരുന്നിനെക്കുറിച്ച് ഉയരുന്ന സംശയങ്ങൾ എന്തൊക്കെയാണ് ? 5 . അർബുദമരുന്നുകൾക്ക് തീപിടിച്ച വില എന്തുകൊണ്ട് ? ആരോഗ്യനയം എങ്ങനെ പരിഷ്കരിക്കപ്പെടണം ? 6 . പുതിയ മരുന്ന് വിജയമാണെങ്കിൽ മരുന്ന് ലോകത്ത് ലഭ്യമാകാൻ എത്രസമയമെടുക്കും ? തിരുവനന്തപുരം Sree Chitra Tirunal Institute for Medical Sciences & Technology ൽ നിന്നും PhD കരസ്ഥമാക്കിയ ഡോക്ടർ വിജയ് ജോസഫ് പന്ത്രണ്ടുകൊല്ലങ്ങളായി Memorial Sloan Kettering Cancer Center (MSKCC ) ലാണ് . പോഡ്‌കാസ്റ്റിലേക്ക് സ്വാഗതം . സ്നേഹപൂർവ്വം എസ് . ഗോപാലകൃഷ്ണൻ 11 ജൂൺ 2022 ഡൽഹി https://www.dillidalipodcast.com/

This week on Pharm5: Novavax protein-based COVID-19 vaccine Pneumococcal Vaccine Decision Tree Dupixent (dupilumab) for atopic dermatitis in kids 6 months to 5 years Dostarlimab 100% effective in Phase II colorectal cancer trial CHIP and Medicaid COVID-19 vaccine counseling codes References: FDA Briefing Document Novavax COVID-19 Vaccine. FDA.gov. https://bit.ly/3tsOBxb. Published June 7, 2022. Accessed June 9, 2022. Haslett C, Carrington AE. ABC News. https://abcn.ws/3O2JtI3. Published June 7, 2022. Accessed June 9, 2022. Protecting adults against pneumococcal disease. National Foundation for Infectious Diseases. https://bit.ly/3aKYXlz. Published June 3, 2022. Accessed June 9, 2022. Brunk D. Dupilumab approved for eczema for children 6 months to 5 years. Medscape. https://wb.md/3QoWAFF. Published June 7, 2022. Accessed June 9, 2022. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2201445 COVID-19 Stand-alone Vaccine Counseling-specific HCPCS Codes. Federal Policy Guidance | Medicaid.gov. https://bit.ly/3QffkY0. Published June 8, 2022. Accessed June 9, 2022.

Dostarlimab Cancer Drug 100% Success Rate | Have we finally defeated Cancer? FUNNY BLUNT TRUTH PODCAST Subscribe! -Youtube -iTunes -Spotify -Amazon Podcasts -Google Podcasts #dostarlimab #dostarlimabdrug #cancer #cancertreatment #cancerdrug #colorectalcancer #medicine #medicalscience #podcast #funnyblunttruth #funnyblunttruthpodcast

La muestra de este estudio sobre cáncer rectal fue pequeña: solo 18 personas se sometieron al tratamiento del fármaco dostarlimab durante seis meses. Pero la enfermedad desapareció en todos los pacientes y fue indetectable mediante examen físico, endoscopía, escaneos PET y resonancias magnéticas.

Dostarlimab: El fármaco experimental que eliminaría el cáncer de colon en 6 meses ¿qué sabemos al respecto?

La muestra de este estudio sobre cáncer rectal fue pequeña: solo 18 personas se sometieron al tratamiento del fármaco dostarlimab durante seis meses. Pero la enfermedad desapareció en todos los pacientes y fue indetectable mediante examen físico, endoscopía, escaneos PET y resonancias magnéticas.

Sochil Martín, habló en exclusiva para el Noticiero Univision sobre su indignación con la próxima sentencia de su abusador el Pastor Nassón García.La Casa Blanca anunció finalmente la lista de los países que asistirán y se resaltan notorias ausencias de regímenes autoritarios.Senadores demócratas y republicanos nos e ponen de acuerdo acerca de la discusión desatada por el tema del control de armas.DOSTARLIMAB, el medicamento experimental para tratar uno de los tipos de cáncer que cobra más vidas está dando resultados esperanzadores.

Se radican cargos criminales contra un hombre de La Florida que presuntamente violó a decenas de mujeres durante décadas, el sujeto es conocido como el violador de la almohada.Víctimas de acoso sexual por parte de lideres de la iglesia de "La Luz del Mundo" hablan de la sentencia que enfrentará su líder, Naasón Merarí Joaquín García.Hispana hace historia luego que fuera aceptada en una de las universidades más prestigiosas del mundo.

In this episode,  Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancerUpdate from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancerResults from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancerPresenters:Nicole Concin, MD, PhDProfessorDepartment of Gynaecology and ObstetricsMedical University InnsbruckInnsbruck, AustriaConsultant in Gynaecological OncologyDepartment of Gynaecology and Gynaecologocial OncologyKEM Evang. Kliniken Essen-MitteEssen, GermanyContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/30PjPnl

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapyA preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancerQuality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancerPresenters:Prof. Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, FranceBernard Doger de Spéville, MD, PhDMedical OncologistSTART-Madrid, Early Phase Clinical Trials UnitHospital Fundación Jiménez DíazMadrid, SpainContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/3dAttwi 

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR statusA subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or ≥2 prior lines of therapyData from the TOTEM trial reporting survival outcomes for patients undergoing intensive vs minimalist follow-up in following treatment for endometrial cancerAn exploratory analysis from the phase III ARIEL3 trial evaluating characteristics of patients with ovarian cancer with exceptional benefit from rucaparibA post hoc analysis from the phase III NORA trial assessing efficacy of starting PARP inhibitor maintenance following either ≤4 vs >4 cycles of platinum-based chemotherapyHighly anticipated results from the phase III EMPOWER-CERVICAL 1 trial of cemiplimab vs investigator's choice chemotherapy in women with cervical cancerPresenters:Domenica Lorusso, MD, PhDAssociate ProfessorGynecologic Oncology DepartmentClinical Research UnitFondazione Policlinico Gemelli IRCCSRome, ItalyAlexandra Leary, MD, PhDMedical Oncologist and Team Leader  Gynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/3dAttwi

Listen to a soundcast of the August 17, 2021, and August 19, 2021, FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced solid tumors, and Opdivo (nivolumab) for the adjuvant treatment of patients with urothelial carcinoma

This week, we'll be reviewing two recent FDA approvals in the oncology space, for patients with mismatch repair–deficient, or dMMR, recurrent or advanced solid tumors, and for adult patients with cancers associated with von Hippel-Lindau (VHL) disease.Coverage of stories discussed this week on ascopost.com:FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid TumorsFDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau DiseaseTo listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including:  Adding bevacizumab to chemotherapy in frontline endometrial cancerLenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancerPARP inhibitor maintenance in ovarian cancerBevacizumab with or without PARP inhibitors in ovarian cancerPresenters:Linda R. Duska, MD, MPHLawrence W. Penniston MD Family Professor in Women's Oncology ResearchDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyUniversity of Virginia School of MedicineCharlottesville, VirginiaRobert L. Coleman, MD, FACOG, FACSGynecologic Oncologist and Chief Scientific OfficerUS Oncology, US Oncology ResearchThe Woodlands, TexasLeslie Randall, MD, MAS  Diane Harris Wright Professor and DirectorDivision of Gynecologic OncologyDepartment of Obstetrics and GynecologyMassey Cancer CenterVirginia Commonwealth UniversityRichmond, VirginiaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/3e6pZCM 

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancerUpdated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancerResults from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancerHighly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancerA post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancersPresenters:David Scott Miller, MD, FACOG, FACSAmy and Vernon E. Faulconer Distinguished Chair in Medical ScienceDirector and Dallas Foundation Chair in Gynecologic OncologyProfessor of Obstetrics & GynecologyUniversity of Texas Southwestern Medical CenterMedical Director of Gynecologic OncologyChair, Cancer CommitteeParkland Health & Hospital SystemDallas, Texas  Melissa M. Hardesty, MD, MPHAffiliate Associate ProfessorOB/GYN/GYN OncologyUniversity of Alaska AnchorageGynecologic Oncologist and Managing PartnerAlaska Women's Cancer CareAnchorage, AlaskaContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/3dAttwi

Two brand new drugs to discuss and their possible roles in practice. Plus, updates on the treatment of HER2-amplified gastric cancer and colorectal cancer.

This week, we'll discuss the findings of a trial that examined the efficacy of intensified therapy for patients with newly diagnosed locally advanced rectal cancer. Then, we'll talk about the FDA's approval of a new agent for advanced endometrial cancer.Coverage of stories discussed this week on ascopost.com:Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal CancerFDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial CancerTo listen to more podcasts from ASCO, visit asco.org/podcasts.

Listen to a soundcast of the April 22 & 23 2021 FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced endometrial cancer and Zynlonta (loncastuximab tesirine-ipyl) for relapsed or refractory large B-cell lymphoma.